Cite
HARVARD Citation
Davar, D. et al. (n.d.). 394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results. Journal for immunotherapy of cancer. p. A419. [Online].